• Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
    May 15 2025

    In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.

    Show more Show less
    4 mins
  • Microplastics in brain, salary gap in neurology, the neurology of space
    May 1 2025

    In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles finding microplastics in the brain postmortem linked to dementia, the salary gap between men and women neurologies, and neurologists studying the impact of microgravity on the brain.

    Show more Show less
    4 mins
  • Impact of high-dose Vitamin D on MS relapse, the role of AI in neurology education, and a 4D animal model that shows precursors of MS lesions before they appear.
    Apr 17 2025

    In this episodeof Neurology Today in 5, Neurology Today editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a large trial that found high-dose Vitamin D reduced MRI evidence of disease activity in patients with clinically isolated syndrome or early relapsing MS; an animal brain map, revealing changes in inflammation, immune activity, and cell repair that preceded the appearance of MS lesions; and a discussion of the challenges and opportunities of using AI in neurology education.

    Show more Show less
    5 mins
  • New approved drug for neurofibromatosis 1 with plexiform neurofibromas, multidisciplinary clinics in neurology, impact of cuts to DEI research grants
    Apr 3 2025

    In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the newly approved drug for neurofibromatosis 1 with plexiform neuromas in adults, how neurology practices are integrating with multiple subspecialties, and the impact of federal cuts to DEI grants and research.

    Show more Show less
    5 mins
  • Impact of NIH cuts on neurology research, response to ACP’s guideline on migraine, an updated position on seizures, driver licensure, and medical reporting
    Mar 20 2025

    In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the impact of NIH cuts to indirect research costs, response to a new guideline on migraine prevention from ACP, and an updated position statement from the AAN on seizures, driver licensures, and medical reporting.

    Show more Show less
    5 mins
  • Lifetime burden of dementia, hidden features on EEGs for epilepsy detection, neurology-trained pharmacists
    Mar 6 2025

    In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the larger lifetime burden of dementia than projected, an AI-fueled program that detects hidden features in EEGs for epilepsy detection, and neurology-trained pharmacists who are working with neurology departments.

    Show more Show less
    5 mins
  • IVF and MS relapse, community-based neurologists doing clinical research, and the loneliness protein implicated in brain function.
    Feb 20 2025

    In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on new data on IVF safety for women with MS, an elevated protein associated with loneliness, social isolation and brain function, and the role of community-based neurologists in drug development.

    Show more Show less
    5 mins
  • Remote neurology education, tirzepatide for obesity-related OSA, artificial intelligence for glioma assessment
    Feb 6 2025

    In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the pros and cons of virtual neurology education, the FDA approval of tirzepatide for obesity-related obstructive sleep apnea, and the promise of AI for glioma assessment.

    Show more Show less
    5 mins
adbl_web_global_use_to_activate_T1_webcro805_stickypopup